CRISPR Therapeutics AG
CRSP
Rang în acțiuni
#3540
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering... CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Preț acțiune
$50.26
Capitalizare de piață
$4.86B
Schimbare (1 zi)
0.43%
Schimbare (1 an)
-32.06%
Țară
CH
Tranzacționează CRISPR Therapeutics AG (CRSP)
Categorie
Healthcare
Raport P/E pentru CRISPR Therapeutics AG (CRSP)
Raport P/E la data de October 2026 TTM: -10.55
Conform celor mai recente rapoarte financiare și prețului acțiunilor CRISPR Therapeutics AG, raportul P/E actual (TTM) este -10.55. La sfârșitul anului 2023, compania avea un P/E de -32.28.
Istoricul raportului P/E pentru CRISPR Therapeutics AG din 2014 până în 2026
Raportul P/E la sfârșitul fiecărui an
| An | Raport P/E | Schimbă |
|---|---|---|
| 2026 (TTM) | -10.55 | 16.32% |
| 2024 | -9.07 | -71.92% |
| 2023 | -32.28 | 564.18% |
| 2022 | -4.86 | -131.90% |
| 2021 | 15.24 | -152.65% |
| 2020 | -28.94 | -158.41% |
| 2019 | 49.55 | -696.60% |
| 2018 | -8.31 | -39.51% |
| 2017 | -13.73 | 28.29% |
| 2016 | -10.70 | -33.03% |
| 2015 | -15.98 | -73.67% |
| 2014 | -60.71 | 0.00% |
Raportul P/E pentru companii similare sau concurenți
| Companie | P/E Ratio | Diferență P/E Ratio | Țara |
|---|---|---|---|
| 28.78 | -372.80% |
US
|
|
| -28.36 | 168.79% |
US
|
|
| -24.57 | 132.85% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -387.48% |
NL
|
Cum interpretezi un P/E ratio?
Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.
Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.
Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.